Questions about COVID-19?

What Patients & Families Need to Know | Visitor Policy | Guidance for Community Healthcare Providers

A photo of Craig Erickson.

Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience

513-636-8375

Board Certified

My Biography & Research

Biography

Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.

Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.

Clinical Interests

Fragile X syndrome; inpatient neurodevelopmental disorders acute crisis stabilization

Research Interests

Fragile X syndrome; autism spectrum disorders; neurodevelopmental disorders; molecular blood markers; quantitative measurement of pathophysiology in developmental disabilities; translational treatment development; psychiatric services for those with developmental disabilities and severe behavior

Academic Affiliation

Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience

Divisions

Psychiatry, Psychiatry

My Locations

My Education

MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2003.

MS: Indiana University School of Medicine, Indianapolis, IN, 2008.

Residency and Fellowship: Indiana University School of Medicine, Indianapolis, IN, 2003-2008.

Certification: Child and Adolescent Psychiatry, 2009; Adult Psychiatry, 2008.

My Publications

Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome. Fitzpatrick, SE; Schmitt, LM; Adams, R; Pedapati, EV; Wink, LK; Shaffer, RC; Sage, J; Weber, JD; Dominick, KC; Erickson, CA. Journal of Autism and Developmental Disorders. 2020; 50:1056-1063.

The relationship between expressive language sampling and clinical measures in fragile X syndrome and typical development. Shaffer, RC; Schmitt, L; Thurman, AJ; Abbeduto, L; Hong, M; Pedapati, E; Dominick, K; Sweeney, J; Erickson, C. Brain Sciences. 2020; 10:66-66.

Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study. Hong, MP; Eckert, EM; Pedapati, EV; Shaffer, RC; Dominick, KC; Wink, LK; Sweeney, JA; Erickson, CA. Journal of Neurodevelopmental Disorders. 2019; 11.

Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes. Feliciano, P; Zhou, X; Astrovskaya, I; Turner, TN; Wang, T; Brueggeman, L; Barnard, R; Hsieh, A; Snyder, LG; Muzny, DM; et al. npj Genomic Medicine. 2019; 4.

Motor cortex facilitation: a marker of attention deficit hyperactivity disorder co-occurrence in autism spectrum disorder. Pedapati, EV; Mooney, LN; Wu, SW; Erickson, CA; Sweeney, JA; Shaffer, RC; Horn, PS; Wink, LK; Gilbert, DL. Translational Psychiatry. 2019; 9.

Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis. Eckert, EM; Dominick, KC; Pedapati, EV; Wink, LK; Shaffer, RC; Andrews, H; Choo, T; Chen, C; Kaufmann, WE; Tartaglia, N; et al. Journal of Autism and Developmental Disorders. 2019; 49:4595-4602.

Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance. Ethridge, LE; De Stefano, LA; Schmitt, LM; Woodruff, NE; Brown, KL; Tran, M; Wang, J; Pedapati, EV; Erickson, CA; Sweeney, JA. Frontiers in Integrative Neuroscience. 2019; 13.

Preventive care services and health behaviors in children with fragile X syndrome. Gilbertson, KE; Jackson, HL; Dziuban, EJ; Sherman, SL; Berry-Kravis, EM; Erickson, CA; Valdez, R. Disability and Health Journal. 2019; 12:564-573.

Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome. McLane, RD; Schmitt, LM; Pedapati, EV; Shaffer, RC; Dominick, KC; Horn, PS; Gross, C; Erickson, CA. Frontiers in Integrative Neuroscience. 2019; 13.

Investigational drugs in early-stage clinical trials for autism spectrum disorder. Hong, MP; Erickson, CA. Expert Opinion on Investigational Drugs. 2019; 28:709-718.